Your Health, We Care
Release date: 2026-01-28 17:30:44 Recommended: 11
Take Revuforj exactly as directed by your healthcare provider. Do not change your dose or stop taking Revuforj unless your healthcare provider tells you to do so.
Adults and Pediatric Patients
Younger than 1 year of age: Not established.
Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Confirm the presence of KMT2A translocation in bone marrow cells.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML): Confirm the presence of NPM1 mutation.
Ensure the white blood cell count is less than 25×10^9/L prior to the initiation of treatment.
Swallow the tablets whole; if swallowing is not possible, crush the tablets and disperse them in water for administration.
Take on an empty stomach or with a low-fat meal (approximately 400 calories, fat ≤25%).
1 year of age and older (≥40 kg): 270 mg twice daily (when no strong CYP3A4 inhibitors are used); 160 mg twice daily (when strong CYP3A4 inhibitors are used).
1 year of age and older (<40 kg): Dosed based on body surface area (BSA): 160 mg/m² twice daily (when no strong CYP3A4 inhibitors are used); 95 mg/m² twice daily (when strong CYP3A4 inhibitors are used); see the full prescribing information for details.
Continue treatment until disease progression or unacceptable toxicity occurs. For patients without disease progression or unacceptable toxicity, treat for at least 6 months.
Keep Revuforj and all medications out of the reach of children.
Before taking Revuforj, inform your healthcare provider of all your medical conditions, including if you:
Have any heart problems, including a condition called long QT syndrome;
Have been told that you have low potassium or magnesium levels in your blood;
Are pregnant or plan to become pregnant. Revuforj may cause harm to an unborn baby;
Are breastfeeding or plan to breastfeed. It is not known whether Revuforj passes into breast milk. Do not breastfeed during treatment with Revuforj and for 1 week after the last dose.
